Analysis populations
The primary endpoint analysis of the patients who achieved SR at week 52 was limited to the cohort of patients who had an opportunity to complete the 52-week treatment period (i.e., week 52 analysis set). This cohort of patients was defined as the patients with a randomization date prior to 16 Oct 2019.The intent-to-treat (ITT) population (i.e., all randomized patients) was used for the efficacy analysis at week 24. The safety population included all randomized patients who received at least one dose of the study medication. The PK population consisted of all patients in the safety population with at least one post-dose, non-missing serum sarilumab concentration.